ReachBio Research Labs has launched cellPrism, a drug development platform designed to deliver a spectrum of customized in-vitro assays to biotechnology and pharmaceutical companies.
"This platform offers clients a broad spectrum of customizable assays to better address their unique program challenges,” Dr. Emer Clarke, chief scientific officer for ReachBio Research Labs, said in a statement. “Additionally, we apply the most clinically relevant assays available at each stage of the client's program challenge, and that can range from early drug development (e.g. target validation) to, and through, data generation for IND submission."
The cellPrism platform specializes in nine toxicology and immunology challenges. It provides assay format testing with multiple read-outs for cells of interest for each challenge. The challenges the toxicology program deals with include neutropenia, thrombocytopenia, anemia and lymphopenia, while the challenges the immunology program deals with are immuno-oncology, cytokine storm, antibody testing, target validation and immuno-phenotyping.
"We've recognized for quite a while, whether through a client experience on our website or directly one-on-one, the need to improve how we approach clients as we expand our services,” Rob Chaney, general manager and chief operations officer, said. “Integrating these assays, and how we go about addressing clients' unique drug development challenges, is something that cellPrism can tackle more effectively.”